Burlington, Ontario

The Jenex Corp. completed three previously announced brokered private placements on Jan. 12, 2006, for total gross proceeds of $1,027,100.

The first private placement raised gross proceeds of $252,100 and resulted in the issuance of 1,800,714 units at a price of 14 cents per unit to investors. Each unit is composed of one common share of the corporation and 0.14 of a non-transferable share purchase warrant (252,100 whole warrants in total). Each whole warrant entitles the holder thereof to purchase one additional common share of the corporation at a price of 25 cents per share for a period of two years commencing from the closing date. In connection with the above, Benson Van Laer & Co. Inc. was paid a commission of $15,900 in cash and 191,316 warrants, on the same terms as the warrants issued to investors.

The second private placement raised gross proceeds of $275,000 and resulted in the issuance of 275,000 units at a price of $1 per unit to investors. Each unit is composed of $1 worth of principal amount of 12 per cent secured convertible debentures with a two-year term and one non- transferable share purchase warrant. The debentures are convertible at the option of the holders into common shares of the corporation at a conversion price of 15 cents per share. Each whole warrant entitles the holder thereof to purchase one additional common share of the corporation at a price of 25 cents per share for a period of two years commencing from the closing date. The debenture is callable by the corporation at any time within the term. The holder will have 30 days wherein they may choose to convert their debenture into common shares or receive payment of their principal and interest accrued to that date. In connection with the above, Benson Van Laer was paid a commission of $25,000 in cash and 191,667 warrants, on the same terms as the warrants issued to investors.

The third private placement raised gross proceeds of $500,000 and resulted in the issuance of 500,000 units at a price of $1 per unit to investors. Each unit is composed of $1 worth of principal amount of 12 per cent secured convertible debentures with a two-year term and 3-1/2 non-transferable share purchase warrants (1.75 million warrants in total). The debentures are convertible at the option of the holder into common shares of the corporation at a conversion price of 15 cents per share. Each whole warrant entitles the holder thereof to purchase one additional common share of the corporation at a price of 25 cents per share for a period of two years commencing from the closing date. The debenture is callable by the corporation at any time within the term. The holders will have 30 days wherein they may choose to convert their debentures into common shares or receive payment of their principal and interest accrued to that date. In connection with the above, Benson Van Laer was paid a commission of $50,000 in cash and 383,333 warrants, on the same terms as the warrants issued to investors.

All of the securities issued pursuant to each of the three private placements (including conversion shares and shares issued upon exercise of the warrants) are subject to a hold period which expires on May 12, 2006.

In addition to the foregoing, the corporation is proposing to complete, subject to regulatory approval, a new brokered private placement of up to 528,350 units at a price of 15 cents per unit to raise up to $79,252.50. Each unit will consist of one common share of the corporation and 0.15 of a non-transferable share purchase warrant (79,253 whole warrants in total). Each whole warrant will entitle the holder thereof to purchase one additional common share of the corporation at a price of 25 cents per common share for a period of two years following the closing date of the private placement. In connection with the foregoing, the corporation proposes to pay a finder's fee to Benson Van Laer composed of $2,990 in cash and 19,935 warrants, on the same terms as the warrants issued to investors.

In addition, the corporation has agreed to grant, subject to regulatory approval, 645,000 incentive stock options to purchase common shares of the corporation, exercisable at a price of 40 cents per share for a period ending Dec. 31, 2006, to a consultant of the corporation as consideration for consulting services.

About The Jenex Corporation

Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy technology.  Patents in the United States, Canada, Australia, and Europe protect the technology. The first device developed from this technology is the Therapik^® product, for insect stings and bites.  The second device, intercept^CS™ is the first product proven and approved to prevent cold sores.  Jenex has been approved to market intercept^CS in Canada with its approved claim, “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. The Corporation is preparing for the launch of intercept^CS in the Canadian market in the first quarter 2006.  Regulatory approvals are being pursued for USA, Europe and Australia. It is estimated that between 45 and 90 million people in North America suffer from recurrent cold sores.  More information about the Corporation can be found at:  www.jenexcorp.com . 

Enquiries:

Michael A. Jenkins, President

The Jenex Corporation

940 Sheldon Court, Suite 207

Burlington, Ontario

L7L 5K6

Telephone:  (905) 632-3830

Facsimile:    (905) 632-3774

Email:          jenex@jenexcorp.com